Results 41 to 50 of about 4,484 (145)

Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.

PLoS ONE, 2023
BackgroundInsurers manage the cost of specialty medicines via rebates, however it is unclear if the savings are passed on to patients, and whether reducing rebates may lead to changes in patient out-of-pocket (OOP) costs and medication adherence.
William Bruce Wong, Arpamas Seetasith, Anna Hung, Leah L Zullig   +3 more
doaj   +1 more source

Disrupting Viral Persistence: CRISPR/Cas9‐Based Strategies for Hepatitis B and C Treatment, and Challenges

Journal of Cellular and Molecular Medicine, Volume 30, Issue 1, January 2026.
ABSTRACT Hepatitis B and C viruses (HBV and HCV) remain among the leading causes of liver disease worldwide. Current antiviral drugs, such as nucleotide analogues (NAs), can reduce the replication of new HBV and HCV infections but cannot completely eliminate chronic infections.
Meng‐Fan Li, Akmal Zubair, Safa Wdidi, Shan He   +3 more
wiley   +1 more source

Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations

Informatics in Medicine Unlocked, 2021
Background: Different approaches have been proved effective for combating the COVID-19 pandemic. Accordingly, in silico drug repurposing strategy, has been highly regarded as an accurate computational tool to achieve fast and reliable results ...
Soodeh Mahdian, Mahboobeh Zarrabi, Yunes Panahi, Somayyeh Dabbagh   +3 more
doaj   +1 more source

Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C

International Journal of Hepatology, Volume 2026, Issue 1, 2026.
Aim The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (
Seiichi Tawara, Asuka Watanabe, Junya Yamaguchi, Mai Omi, Tetsuro Miyazaki, Haruka Taguchi, Ryosuke Kiyota, Takuo Yamai, Shoichiro Kawai, Takuya Inoue, Takayuki Yakushijin, Dirk Uhlmann   +11 more
wiley   +1 more source

Evaluation of Characteristics and Ethnic Sensitivity for FDA‐Approved Drugs with Racial and Ethnic Differences in Pharmacokinetics, Safety, and Efficacy

The Journal of Clinical Pharmacology, Volume 65, Issue 11, Page 1381-1391, November 2025.
Abstract Racial and ethnic differences in drug disposition and response may have a significant impact on its risk‐benefit balance. Therefore, it is important to examine whether an investigational drug has characteristics that make the pharmacokinetics (PK), safety, and efficacy likely to be affected by intrinsic and extrinsic ethnic factors based on ...
Kei Fukuhara, Yusuke Tanetsugu, Shinsuke Wada, Chieko Muto, Norisuke Kawai   +4 more
wiley   +1 more source

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study

Caspian Journal of Internal Medicine, 2020
Background: Treatment of hepatitis C virus (HCV) infection with recently introduced direct-acting antiviral agents (DAA) is effective and safe, however there is little known regarding safety and efficacy of generic DAAs in the real-life clinical setting.
Heidar Sharafi, Seyed Hoda Alavian, Bita Behnava, Mohammad Saeid Rezaee-Zavareh, Mehri Nikbin, Seyed Moayed Alavian   +5 more
doaj  

Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease

The Korean Journal of Gastroenterology, 2016
Article: Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease (Gastroenterology 2015;149:649-659)
Woo Jin Chung
doaj   +1 more source

Small Molecule Targeting of Atypical p38 Protects Against Viral Infection

The FASEB Journal, Volume 39, Issue 20, 31 October 2025.
Targeting host signaling pathways offers a complementary strategy to direct‐acting antivirals. Small‐molecule modulators of atypical p38 block Hepatitis C virus replication and also inhibit Human Cytomegalovirus. By disrupting virus‐induced p38 activation, these compounds suppress viral RNA replication and protein expression, highlighting atypical p38 ...
Fredejah T. Royer, Jeremy C. Burton, Johnathan Burns, Megan G. Lloyd, Reuben Onwe, Jennifer F. Moffat, Neil J. Grimsey   +6 more
wiley   +1 more source

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CLpro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates [version 1; peer review: 2 approved]

F1000Research, 2020
We prepared the three-dimensional model of the SARS-CoV-2 (aka 2019-nCoV) 3C-like protease (3CLpro) using the crystal structure of the highly similar (96% identity) ortholog from the SARS-CoV. All residues involved in the catalysis, substrate binding and
Yu Wai Chen, Chin-Pang Bennu Yiu, Kwok-Yin Wong   +2 more
doaj   +1 more source

Multicomponent Synthesis of Fluorine‐Containing Bioactive Compounds and Drugs

European Journal of Organic Chemistry, Volume 28, Issue 38, October 15, 2025.
Multicomponent reactions are robust synthetic tools to assamble complex polyheterocycles and other interesting molecular architectures with potential application in medicinal chemistry, including their fluorine‐containing analogues. Fluorine atoms placed strategically into bioactive molecules often enhance essential pharmacokinetic parameters like ...
Ivette Morales‐Salazar, Perla Islas‐Jácome, Leonardo D. Herrera‐Zuñiga, Samuel Couve‐Bonnaire, Philippe Jubault, Eduardo González‐Zamora, Jean‐Philippe Bouillon, Alejandro Islas‐Jácome   +7 more
wiley   +1 more source